BioLineRx, Ltd., Israel’s leading specialized drug development company, today announced that it has signed two license agreements for the development and commercialization of BL-2050, for the treatment of peripheral vascular disease (PVD) and BL-2060, a novel antibiotic. The worldwide exclusive license agreements were signed with Ramot at Tel Aviv University and The Technion Research and Development Foundations (TRDF) respectively. BioLineRx plans to develop the projects through BioLine Innovations Jerusalem (BIJ) under the National Biotech Grant received in November 2004 from the Israeli Office of the Chief Scientist. BL-2050 has already received approval for entry into the BIJ program and BL-2060 will be submitted for review in the coming weeks.
